TAE Technologies logo

TAE Technologies, Inc.

Energy Technology

TAE Technologies Stock

TAE Technologies is a pioneering energy company focused on developing innovative clean energy solutions through advanced fusion power technology. They strive to produce the ultimate carbon-free energy source, aiming for both environmental sustainability and economic competitiveness. TAE Technologies also explores related technologies, including power management systems for e-mobility and advanced cancer treatment methods, demonstrating a broad commitment to improving global health and energy resources.

Founded: 1998

TAE Technologies Website

For more TAE Technologies stock information, or to buy or sell private shares, sign up for a MicroVentures account.

TAE Technologies Company Overview

TAE Technologies (formerly known as Tri Alpha Energy) is at the forefront of fusion power technology, working towards developing commercial fusion power with the cleanest environmental profile. Their main focus is on creating a compact, cost-effective fusion power source that could sustainably power the planet for centuries. TAE Technologies' innovative approach involves proprietary science and engineering, which has positioned them as leaders in the clean energy sector. TAE’s fusion technology, particularly their work with hydrogen-boron fusion, is designed to be a safer and more efficient energy alternative. This technology harnesses the power of an abundant and environmentally friendly fuel source, aiming to provide electricity through the cleanest and most economical path possible. In addition to their energy solutions, TAE Technologies is also leveraging their technological advances in accelerator beams to pioneer next-generation cancer treatment options. Their work in Boron Neutron Capture Therapy (BNCT) offers new hope for treating difficult cancers with cellular-level precision. The company's growth and expansion into various technological sectors, including power solutions and life sciences, illustrate their broader mission beyond just energy generation. TAE Technologies collaborates with numerous prestigious institutions and industry leaders, further cementing their position as an innovative force in both the energy and healthcare sectors. With a clear focus on sustainability and innovation, TAE Technologies continues to drive significant advancements in fusion technology and beyond, aiming to build a sustainable and healthier future for all.

Management Team

Dr. Michl Binderbauer CEO
David R. Ewing Chief Information & Communications Officer
Ken Roberts General Counsel
Dr. Artem Smirnov CTO
Dr. Toshiki Tajima Chief Science Officer

Funding Information

News

Truth Social Parent to Merge With Nuclear Fusion Firm in $6 Billion Deal

Trump Media & Technology Group and TAE Technologies, a fusion power company, said Thursday they had agreed to an all-stock merger that the companies valued at more than $6 billion.

TAE, UKAEA create joint venture

US private fusion energy company TAE Technologies and the UK Atomic Energy Authority have announced a bilateral and reciprocal investment commitment to commercialise TAE's proprietary particle accelerator technology for the global market.

TAE Technologies Raises $150 Million in Latest Funding Round

/PRNewswire/ -- TAE Technologies ("TAE"), the leading fusion energy company developing the cleanest and safest approach to commercial fusion power, today...

TAE Technologies Delivers Fusion Breakthrough that Dramatically Reduces Cost of a Future Power Plant

/PRNewswire/ -- TAE Technologies, a private fusion energy company developing the cleanest and safest approach to commercial fusion power, has achieved a...

World's Top GreenTech Companies of 2025

TIME and Statista have named 250 companies reducing environmental impact around the globe

TAE Life Sciences and CNAO Announce Definitive Agreement on BNCT, a Next-Generation Cancer Therapy

PAVIA, Italy--(BUSINESS WIRE)--Dec 17, 2024-- TAE Life Sciences (TLS), a leading developer of Boron Neutron Capture Therapy (BNCT) systems and drugs, and the Italian National Center for Oncological Hadrontherapy (CNAO), a premier hadrontherapy center in Europe, today announced a definitive agreement to collaborate on groundbreaking global drug